Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-1)
A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC
Sponsor: AbbVie
A PHASE2 clinical study on Hepatocellular Carcinoma, this trial is ongoing. The trial is conducted by AbbVie and has accumulated 21 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
21 versions recorded-
Dec 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2
-
Feb 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Jan 2025 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 16 earlier versions
-
Nov 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Mar 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2023 — Sep 2023 [monthly]
Not Yet Recruiting PHASE2
-
May 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Asheville, United States , Barcelona, Spain , Baton Rouge, United States , Bologna, Italy , Boston, United States , Chapel Hill, United States , Chiba, Japan , Chicago, United States , Clichy, France , Córdoba, Spain and 43 more locations